IPSC Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.37
- P/S (TTM)
- 3.72
- EV/EBITDA
- 131.51
Profitability & growth
- ROE (TTM)
- -49.6%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 1.67
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Century Therapeutics Inc
Company profileCentury Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging its pioneering induced pluripotent stem cell (iPSC) technology, Century is committed to developing innovative off-the-shelf therapeutics designed to improve patient outcomes and expand accessibility to care. With a diverse array of clinical-stage assets and strategic collaborations that enhance its market position, Century Therapeutics presents compelling investment opportunities in the burgeoning cell therapy…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 25 NORTH 38TH STREET, PHILADELPHIA, PA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
